Across TCGA pan-cancer cohorts, DEPTOR Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DEPTOR data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher DEPTOR Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DEPTOR expression acts as an unfavorable survival marker.
PRAD and UCEC are the cancer types where DEPTOR Mutation most reproducibly stratifies survival.